Morgan Stanley Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $28
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
Morgan Stanley analyst Judah Frommer initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $28.
Morgan Stanley analyst Judah Frommer initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $28.